Artificial intelligence-assisted colonoscopy to identify histologic remission and predict the outcomes of patients with ulcerative colitis: A systematic review
This systematic review evaluated the current status of AI-assisted colonoscopy to identify histologic remission and predict the clinical outcomes of patients with ulcerative colitis. The use of artificial intelligence (AI) has increased substantially across several medical fields, including gastrointestinal endoscopy. Evidence suggests that it may be helpful to predict histologic remission and relapse, which would be beneficial because current histological diagnosis is limited by the inconvenience of obtaining biopsies and the high cost and time-intensiveness of pathological diagnosis. (Source: Digestive and Liver Disease)
Source: Digestive and Liver Disease - April 21, 2024 Category: Gastroenterology Authors: Yasuharu Maeda, Shin-ei Kudo, Giovanni Santacroce, Noriyuki Ogata, Masashi Misawa, Marietta Iacucci Tags: Alimentary Tract Source Type: research
Patients with Inflammatory Bowel Disease who regularly consume fruits and vegetables present lower prevalence of disease activation: a cross-sectional study
Exclusion diets are common practices among individuals with Inflammatory Bowel Disease (IBD). Reports that certain foods trigger or worsen symptoms are recurrent but lack evidence. The aim of the study was to identify which foods were most frequently avoided by patients with Crohn's Disease (CD) and Ulcerative Colitis (UC) and whether the consumption of any food group was associated with disease activity. (Source: Clinical Nutrition ESPEN)
Source: Clinical Nutrition ESPEN - April 20, 2024 Category: Nutrition Authors: Patr ícia Sauer, Vivian Cristine Luft, Valesca Dall’Alba Source Type: research
Extensive colitis associated with ixekizumab
We present the clinical case of a 56-year-old former smoker female, with a family history of maternal ulcerative colitis and personal history of ankylosing spondylitis treated with Ixekizumab for 3 months, who was admitted for fever, left iliac fossa pain and diarrhea without pathological products of 2 weeks of evolution. Abdominopelvic computed tomography scan identified pancolitis. Complete colonoscopy revealed continuous involvement of the proximal colon (right and transverse colon presented deep ulcerations and mucosal friability) with preservation of the terminal ileum. After many complementary tests and according to ...
Source: Revista Espanola de Enfermedades Digestivas - April 18, 2024 Category: Gastroenterology Authors: Mar ía Luisa López García Mar ía Paz Arreba González Leire Irusta Olano Carmen Mu ñoz Villafranca Source Type: research
Inflammatory bowel disease: recent developments
Paediatric-onset inflammatory bowel disease (IBD) is a complex and heterogenous condition. Incidence of disease in those aged <18 years has doubled over the last 25 years, with concurrent increased prevalence and no decrease in disease severity. The tools available at diagnosis for investigation have developed over the last 10 years, including better utilisation of faecal calprotectin, improved small bowel imaging and video capsule endoscopy. Alongside this, management options have increased and include biological and small molecule therapies targeting alternative pathways (such as interleukin 12/23, integrins and Janus...
Source: Archives of Disease in Childhood - April 18, 2024 Category: Pediatrics Authors: Ashton, J. J., Beattie, R. M. Tags: Open access Review Source Type: research
A Response-able Diagnosis: Type 2 Autoimmune Pancreatitis in the Setting of Ulcerative Colitis
(Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - April 18, 2024 Category: Gastroenterology Source Type: research
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
ConclusionInitiating IV VDZ and switching to SC treatment was associated with high persistence rates and improvements in measures of QoL and FCP. These findings are reassuring for patients who start IV VDZ and switch to SC VDZ.Graphical Abstract (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - April 18, 2024 Category: Gastroenterology Source Type: research
Short-chain fatty acid-producing bacterial strains attenuate experimental ulcerative colitis by promoting M2 macrophage polarization via JAK/STAT3/FOXO3 axis inactivation
Patients with inflammatory bowel disease (IBD), dysbiosis, and immunosuppression who receive fecal microbiota transplantation (FMT) from healthy donors are at an increased risk of developing bacteremia. This s... (Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - April 18, 2024 Category: Research Authors: Hailan Zhao, Youlian Zhou, Jing Xu, Yong Zhang, Hong Wang, Chong Zhao, Hongli Huang, Jing Yang, Chen Huang, Yingfei Li, Lisheng Wang and Yuqiang Nie Tags: Research Source Type: research
Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis
Clin Pharmacol Ther. 2024 Apr 16. doi: 10.1002/cpt.3251. Online ahead of print.ABSTRACTRitlecitinib, an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family inhibitor, was evaluated in patients with ulcerative colitis (UC) in a phase 2b trial. Model-informed drug development strategies were applied to bridge observations from phase 2b to predictions for a proposed phase 3 study design to assess the probability of achieving the target efficacy outcome. A longitudinal exposure-response model of the time course of the 4 Mayo subscores (rectal bleeding, stool frequency, physician's global assessment...
Source: Clinical Pharmacology and Therapeutics - April 17, 2024 Category: Drugs & Pharmacology Authors: Jessica Wojciechowski Arnab Mukherjee Christopher Banfield Timothy Nicholas Source Type: research
Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis
Clin Pharmacol Ther. 2024 Apr 16. doi: 10.1002/cpt.3251. Online ahead of print.ABSTRACTRitlecitinib, an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family inhibitor, was evaluated in patients with ulcerative colitis (UC) in a phase 2b trial. Model-informed drug development strategies were applied to bridge observations from phase 2b to predictions for a proposed phase 3 study design to assess the probability of achieving the target efficacy outcome. A longitudinal exposure-response model of the time course of the 4 Mayo subscores (rectal bleeding, stool frequency, physician's global assessment...
Source: Clinical Pharmacology and Therapeutics - April 17, 2024 Category: Drugs & Pharmacology Authors: Jessica Wojciechowski Arnab Mukherjee Christopher Banfield Timothy Nicholas Source Type: research
Defining predictors of responsiveness to advanced therapies in Crohns disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine
Introduction
Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient’s quality of life. Therapeutic developments in the last 20 years have revolutionised treatment. However, clinical trials and real-world data show primary non-response rates up to 40%. A significant challenge is an inability to predict which treatment will benefit individual patients.
Current understanding of IBD pathogenesis implicates complex interactions between host genetics and the gut microbiome. Most cohorts s...
Source: BMJ Open - April 17, 2024 Category: General Medicine Authors: Wyatt, N. J., Watson, H., Anderson, C. A., Kennedy, N. A., Raine, T., Ahmad, T., Allerton, D., Bardgett, M., Clark, E., Clewes, D., Cotobal Martin, C., Doona, M., Doyle, J. A., Frith, K., Hancock, H. C., Hart, A. L., Hildreth, V., Irving, P. M., Iqbal, S. Tags: Open access, Gastroenterology and hepatology Source Type: research
Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials
ConclusionsA comprehensive analysis revealed that tofacitinib has a positive effect on addressing skin and joint symptoms, as well as improving the quality of life for patients with chronic plaque psoriasis and psoriatic arthritis (PsA). However, the safety of the drug ’s long-term usage even requires further validation.Key Points• In 6 analyses involving a total of 1393 patients, tofacitinib exhibits positive effect on the treatment of both chronic plaque psoriasis and psoriatic arthritis (PsA).• Although dose-based subgroup analyses have demonstrated effectiveness. Some studies indicate that the 5-mg dose (twice da...
Source: Clinical Rheumatology - April 16, 2024 Category: Rheumatology Source Type: research
A New Risk Prediction Model for Detecting Endoscopic Activity of Ulcerative Colitis
CONCLUSIONS: : The nomogram, which incorporated activated partial thromboplastin time, fecal occult blood test, β2-globulin level, and fibrinogen degradation products, served as a prospective tool for evaluating UC activity in clinical practices.PMID:38623059 | DOI:10.5009/gnl230370 (Source: Gut and Liver)
Source: Gut and Liver - April 16, 2024 Category: Gastroenterology Authors: Guoyu Guan Sangdan Zhuoga Songbai Zheng Kangqiao Xu Tingwen Weng Wensi Qian Danian Ji Xiaofeng Yu Source Type: research
